Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

20.68 +0.02 (+0.10%)
Streaming Delayed Price Updated: 10:36 AM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
9 Analysts Have This to Say About Genmab
Via Benzinga
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
7 Must-Buy Stocks That Are on Ridiculous Discount Now
With Wall Street still chasing after the usual suspects in the tech ecosystem, astute investors may wish to target stocks on sale. 
Via InvestorPlace
NASDAQ:GMAB is not too expensive for the growth it is showing.
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced. 
Via Chartmill
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor. 
Via InvestorPlace
Topics Economy
Analyst Expectations for Genmab's Future
Via Benzinga
NASDAQ:GMAB, a strong growth stock, setting up for a breakout.
GENMAB A/S -SP ADR (NASDAQ:GMAB)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)
From Genmab A/S
Via Business Wire
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
From Seagen Inc.
Via Business Wire
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable. 
Via Chartmill
What 13 Analyst Ratings Have To Say About Genmab
Via Benzinga
Expert Ratings for Genmab
Via Benzinga
Analyst Expectations for Genmab's Future
Via Benzinga
United Airlines, Interactive Brokers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Don’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher
With their seamless blend of promise and innovation, these biotech stocks to buy offer a strategic gateway to fortify your portfolio. 
Via InvestorPlace
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
From Genmab A/S
Via Business Wire
Analyst Expectations for Genmab's Future
Via Benzinga
12 Analysts Have This to Say About Genmab
Via Benzinga
Why Shares of Iovance Biotherapeutics Dropped Thursday
The biotech stock's lead therapy is looking at some competition. 
Via The Motley Fool
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients  
Via Benzinga
Why Shares of Zai Lab Limited Were Jumping on Tuesday
Zai Lab's shares benefited from positive clinical trial news. 
Via The Motley Fool
Encouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New Indications
Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) released topline data from the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on... 
Via Benzinga
Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone
From Seagen Inc.
Via Business Wire
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
From Genmab A/S
Via Business Wire
The 3 Most Promising Biotech Stocks to Own Now
These top biotech stock picks with high and leading growth potential are must-owns for investors looking for high upside potential. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023
Via Benzinga
Is AbbVie Still a Good Dividend Stock to Buy?
Find out if AbbVie can overcome sinking sales of its top-selling product. 
Via The Motley Fool
3 Things About Johnson & Johnson Every Smart Investor Knows
The company has been a strong value stock but faces big changes this year. 
Via The Motley Fool
3 Biotech Stocks You Better Be Buying on Each and Every Dip
Biotech companies can bring about life-changing innovations. We've created a list to help you find the best biotech stocks out there. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.